Form 8-K

8-K — Inmune Bio, Inc.

Accession: 0001213900-26-083961

Filed: 2026-07-31

Period: 2026-07-31

CIK: 0001711754

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0300069-8k_inmune.htm (Primary)

EX-99.1 — PRESS RELEASE DATED JULY 31, 2026 (ea030006901ex99-1.htm)

GRAPHIC (ea030006901_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0300069-8k_inmune.htm · Sequence: 1

false

0001711754

2026-07-31

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): July 31, 2026

INMUNE

BIO INC.

(Exact

name of registrant as specified in charter)

Nevada

001-38793

47-5205835

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

225

NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432

(Address

of Principal Executive Offices) (Zip Code)

(561)

710-0512

(Registrant’s

Telephone Number, Including Area Code)

Not

Applicable

(Former

Name or Former Address, If Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, par value

$0.001 per shares

INMB

The NASDAQ Stock Market

LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01. Other Events.

July 31, 2026, INmune Bio Inc. issued a press release announcing that on July 30, 2026, it received a research and development cash rebate

from Australia of approximately $4.2 million.

copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item

9.01 Financial statements and Exhibits

(d)

Exhibits.

99.1

Press Release dated July 31, 2026

104

Cover Page Interactive Data File (embedded within the

Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

INMUNE BIO

INC.

Date: July 31, 2026

By:

/s/

David Moss

Name:

David Moss

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE DATED JULY 31, 2026

EX-99.1

Filename: ea030006901ex99-1.htm · Sequence: 2

Exhibit 99.1

INmune

Bio Receives R&D Rebates of Approximately $4.6 Million

BOCA

RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology

company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate

from Australia of approximately $4.2 million. This rebate is in addition to approximately $0.4 million of rebate from the United

Kingdom during June 2026. After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate

received during the quarter, the combined rebate proceeds exceeded the Company's net cash used in operating activities during the quarter.

The rebates strengthen the Company's balance sheet and extend its cash runway as INmune Bio advances CORDStrom™ (Ebstrocel™)

toward regulatory filings.

“These

rebates are a meaningful financial milestone for INmune Bio and our shareholders,” said David Moss, Chief Executive Officer of

INmune Bio. “Receiving approximately $4.6 million in non-dilutive cash during June and July strengthens our financial position,

extends our runway without issuing additional equity and allows us to preserve momentum across the near-term regulatory and clinical

milestones that we believe can drive substantial value. We are grateful for R&D incentive programs that recognize the

significant investment required to develop new medicines. By supporting innovative biotechnology companies through long and capital-intensive

development programs, these initiatives help advance promising therapies for patients with serious diseases and limited treatment options.”

The

rebates were generated through established government programs designed to support qualifying research and development conducted in the

UK and Australia. They reflect eligible expenditures related to the Company’s clinical-development, manufacturing and regulatory

activities in those jurisdictions.

About INmune Bio

Inc.

INmune

Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate

immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced

precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune

Bio is actively advancing two late-stage product platforms toward registrational milestones:

● CORDStrom™:

A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell

platform engineered to address the historical clinical challenges of donor variability and

manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform

is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026

and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.

● XPro1595™:

A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes

soluble TNF (sTNF) to eliminate neuroinflammation without compromising protective immune

function. Backed by recently granted FDA Fast Track designation and successful regulatory

alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated

Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s

disease.

learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward

Looking Statements

Clinical

trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press

release related to the development or commercialization of product candidates and other business and financial matters, including without

limitation, the amount, timing, accounting treatment and financial impact of R&D rebates; anticipated cash balances, cash burn, net

cash generation and cash runway; trial results and data; the timing of key milestones; future plans or expectations; and the prospects

for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements

as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are

based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and

circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties.

CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in

clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the

UK MHRA or any regulatory body, and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory

body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current

expectations include, but are not limited to, risks and uncertainties relating to foreign exchange rates; finalization of the Company’s

financial statements; the Company’s ability to produce more drug for clinical trials; the availability of substantial additional

funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;

and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission,

including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s

Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance

that may arise after the date of this release.

INmune Bio Contacts:

David Moss

Chief Executive Officer

(561) 710-0512

info@inmunebio.com

Daniel Carlson

Head of Investor Relations

(415) 509-4590

dcarlson@inmunebio.com

GRAPHIC

Filename: ea030006901_ex99-1img1.jpg · Sequence: 3

Binary file (8377 bytes)

Download ea030006901_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jul. 31, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 31, 2026

Entity File Number

001-38793

Entity Registrant Name

INMUNE

BIO INC.

Entity Central Index Key

0001711754

Entity Tax Identification Number

47-5205835

Entity Incorporation, State or Country Code

Entity Address, Address Line One

225

NE Mizner Blvd.

Entity Address, Address Line Two

Suite 640

Entity Address, City or Town

Boca Raton

Entity Address, State or Province

Entity Address, Postal Zip Code

33432

City Area Code

561

Local Phone Number

710-0512

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value

$0.001 per shares

Trading Symbol

INMB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration